TLDR Bernstein elevates Boeing to top Aerospace & Defense selection for 2026 with price target of $298 Production ramping up with 737 at 42 units monthly and 787TLDR Bernstein elevates Boeing to top Aerospace & Defense selection for 2026 with price target of $298 Production ramping up with 737 at 42 units monthly and 787

Boeing (BA) Stock: Named Top Aerospace Pick for 2026 by Major Analyst

TLDR

  • Bernstein elevates Boeing to top Aerospace & Defense selection for 2026 with price target of $298
  • Production ramping up with 737 at 42 units monthly and 787 at 8 units monthly
  • Firm forecasts free cash flow exceeding $11 billion by 2028 as production scales
  • Current backlog so large that only half will be fulfilled by 2030 before new orders
  • Defense division projected to achieve positive cash generation in 2027

Bernstein elevated Boeing to its premier Aerospace & Defense selection for 2026. The investment firm increased its price target to $298 from $277 while maintaining an Outperform rating.


BA Stock Card
The Boeing Company, BA

Analysts led by Douglas Harned expressed growing confidence in Boeing’s recovery trajectory. The firm believes demand will outpace supply through the end of the decade for both Boeing and Airbus.

The $298 target represents 23% upside from the current trading price of $242.61. Shares recently touched a 52-week high of $247.40.

Boeing historically accelerates once investors trust production ramps. The company’s execution on key programs will be critical for stock performance going forward.

Production Rates Drive Optimism

Current production stands at 42 aircraft monthly for the 737 program. The 787 program produces 8 units per month.

These rates are expected to climb over the next five years. Bernstein anticipates improving margins and cash generation as output increases.

The backlog situation is remarkable. By 2030, Boeing will have delivered only half of existing 737 and 787 orders. This doesn’t account for new orders expected in coming years.

Fourth quarter concerns arose around cash flow. Delays in 777X certification and higher capital spending for facility expansion triggered a stock pullback.

Bernstein characterizes the dip as a buying opportunity. The 777X issues relate to timing rather than fundamental problems. The increased capital expenditure is required to address historically large backlogs.

Cash Flow Trajectory Improves

Management projects low single-digit billions in free cash flow for 2026. This guidance includes a $700 million headwind from a Department of Justice settlement.

The outer years look much stronger. Bernstein forecasts free cash flow above $11 billion in 2028 as inventories unwind and production rates accelerate.

Defense operations appear to be stabilizing after years of charges. The F-47 program win should energize Boeing Defense going forward.

The defense segment is projected to return to positive cash generation in 2027. This marks a turnaround after recent struggles.

Boeing Global Services maintains strong performance. High margins continue thanks to aftermarket demand and an expanding commercial mix.

Recent Performance Metrics

Boeing delivered 600 aircraft in 2025, up 72% from the prior year. This marked the highest delivery total since 2018.

The company captured 1,075 net new orders last year. This beat Airbus for the first time in seven years, as the European manufacturer secured 889 orders.

Fourth quarter deliveries reached 160 commercial aircraft. The mix included 737, 767, 777, and 787 Dreamliner models.

Delta Air Lines recently placed an order for up to 60 Boeing 787 Dreamliners. The order includes 30 firm orders for the 787-10 variant plus 30 options.

These deliveries begin in 2031 to support Delta’s international expansion. Bernstein initially upgraded Boeing to Outperform in April 2025 with a $218 target before raising it to the current $298 level.

The post Boeing (BA) Stock: Named Top Aerospace Pick for 2026 by Major Analyst appeared first on Blockonomi.

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.1331
$0.1331$0.1331
+3.04%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Vitalik Buterin Reveals Ethereum’s Bold Plan to Stay Quantum-Secure and Simple!

Vitalik Buterin Reveals Ethereum’s Bold Plan to Stay Quantum-Secure and Simple!

Buterin unveils Ethereum’s strategy to tackle quantum security challenges ahead. Ethereum focuses on simplifying architecture while boosting security for users. Ethereum’s market stability grows as Buterin’s roadmap gains investor confidence. Ethereum founder Vitalik Buterin has unveiled his long-term vision for the blockchain, focusing on making Ethereum quantum-secure while maintaining its simplicity for users. Buterin presented his roadmap at the Japanese Developer Conference, and splits the future of Ethereum into three phases: short-term, mid-term, and long-term. Buterin’s most ambitious goal for Ethereum is to safeguard the blockchain against the threats posed by quantum computing.  The danger of such future developments is that the future may call into question the cryptographic security of most blockchain systems, and Ethereum will be able to remain ahead thanks to more sophisticated mathematical techniques to ensure the safety and integrity of its protocols. Buterin is committed to ensuring that Ethereum evolves in a way that not only meets today’s security challenges but also prepares for the unknowns of tomorrow. Also Read: Ethereum Giant The Ether Machine Takes Major Step Toward Going Public! However, in spite of such high ambitions, Buterin insisted that Ethereum also needed to simplify its architecture. An important aspect of this vision is to remove unnecessary complexity and make Ethereum more accessible and maintainable without losing its strong security capabilities. Security and simplicity form the core of Buterin’s strategy, as they guarantee that the users of Ethereum experience both security and smooth processes. Focus on Speed and Efficiency in the Short-Term In the short term, Buterin aims to enhance Ethereum’s transaction efficiency, a crucial step toward improving scalability and reducing transaction costs. These advantages are attributed to the fact that, within the mid-term, Ethereum is planning to enhance the speed of transactions in layer-2 networks. According to Butterin, this is part of Ethereum’s expansion, particularly because there is still more need to use blockchain technology to date. The other important aspect of Ethereum’s development is the layer-2 solutions. Buterin supports an approach in which the layer-2 networks are dependent on layer-1 to perform some essential tasks like data security, proof, and censorship resistance. This will enable the layer-2 systems of Ethereum to be concerned with verifying and sequencing transactions, which will improve the overall speed and efficiency of the network. Ethereum’s Market Stability Reflects Confidence in Long-Term Strategy Ethereum’s market performance has remained solid, with the cryptocurrency holding steady above $4,000. Currently priced at $4,492.15, Ethereum has experienced a slight 0.93% increase over the last 24 hours, while its trading volume surged by 8.72%, reaching $34.14 billion. These figures point to growing investor confidence in Ethereum’s long-term vision. The crypto community remains optimistic about Ethereum’s future, with many predicting the price could rise to $5,500 by mid-October. Buterin’s clear, forward-thinking strategy continues to build trust in Ethereum as one of the most secure and scalable blockchain platforms in the market. Also Read: Whales Dump 200 Million XRP in Just 2 Weeks – Is XRP’s Price on the Verge of Collapse? The post Vitalik Buterin Reveals Ethereum’s Bold Plan to Stay Quantum-Secure and Simple! appeared first on 36Crypto.
Share
Coinstats2025/09/18 01:22
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26